Used in research to inhibit FGF19 signaling, this antibody helps study metabolic pathways related to bile acid synthesis and glucose metabolism. It is applied in preclinical models to explore liver diseases such as non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. By blocking FGF19 activity, it aids in understanding tumor growth regulation and metabolic dysfunction. Commonly used in immunoassays and in vivo studies to evaluate therapeutic targeting of the FGF19 pathway.